A complete substitute amendment. While v1 focused on prohibiting acts related to counterfeit fentanyl and methamphetamine substances, v2 fundamentally shifts the bill's primary focus to regulating tableting and encapsulating machines and their critical parts to prevent illicit drug manufacturing. v2 also redefines and expands provisions related to counterfeit pills containing illicit synthetic substances, incorporating some themes from v1 but within a new, broader framework.
Stop Pills That Kill Act
- Sponsor
- Rep. Evans, Gabe [R-CO-8]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 16, 2026
Bottom line
The bill aims to disrupt the illicit manufacture of controlled substances, particularly fentanyl, by controlling access to and tracking of pill-making machinery and by enhancing enforcement against dangerous counterfeit pills.
What it actually does
This bill expands the Controlled Substances Act to regulate tableting and encapsulating machines and their critical parts by requiring serial numbers, record-keeping, and reporting for their manufacture, distribution, and sale. It establishes extraterritorial jurisdiction for illicit manufacturing or distribution of these machines and increases penalties for related offenses. Additionally, the bill defines "counterfeit pills containing an illicit synthetic substance" and mandates the DEA to establish an operation plan and submit annual reports to Congress to combat their spread.
Proponents argue
Supporters argue that this bill is a crucial step in combating the opioid crisis and the proliferation of illicit synthetic drugs like fentanyl, which are often pressed into counterfeit pills. By regulating the machines used to create these pills and enhancing law enforcement's ability to track and prosecute illicit manufacturers, the bill will save lives and reduce the availability of dangerous substances.
Opponents contend
Critics might contend that the bill imposes significant regulatory burdens on legitimate manufacturers and distributors of tableting and encapsulating machines, potentially increasing costs for the pharmaceutical industry without effectively deterring illicit actors who may simply acquire machines through unregulated channels or manufacture them covertly.
The bill is relatively short and its core provisions are clearly stated, making it accessible for an informed reader to understand its primary impacts within a reasonable timeframe.
Section 2(a)
Expansion of "Regulated Person" and "Regulated Transaction" Definitions
This section expands the definitions of "regulated person" and "regulated transaction" under the Controlled Substances Act to include individuals and entities involved in the manufacture, distribution, import, or export of tableting machines, encapsulating machines, or their critical parts (like punches and dies). This means that those dealing with these machines will now be subject to the same regulatory oversight as those dealing with listed chemicals.
Supporters argue
Proponents argue that expanding these definitions is essential to close a loophole that allowed illicit drug manufacturers to acquire pill-making machinery without oversight. This brings the tools of illicit drug production under the same scrutiny as the chemical precursors.
Critics contend
Opponents might argue that this expansion could create undue administrative and compliance costs for legitimate businesses in the pharmaceutical and manufacturing sectors, potentially stifling innovation or increasing the cost of legitimate drug production.
Tradeoffs
The bill balances the need for increased control over illicit drug manufacturing tools against the potential for increased regulatory burden on legitimate industries.
Section 2(a)(5)
Definition of "Critical Part" for Tableting/Encapsulating Machines
This provision specifically defines "critical part" for tableting or encapsulating machines to include upper punches, lower punches, and dies. It also grants the Attorney General authority to add other integral parts through future rulemaking. This ensures that key components essential for pill production are also subject to regulation, not just the complete machines.
Section 2(b)(1) & (2)
Serial Number Requirement and Enhanced Record Keeping/Reporting
This section mandates that tableting machines, encapsulating machines, and their critical parts must have a serial number permanently affixed to a nonremovable part. Regulated persons must keep records of these serial numbers and report them to the Attorney General for all regulated transactions. This creates a clear tracking mechanism for these machines and parts.
Section 2(c)
New Prohibited Acts Related to Serial Numbers
This section amends the Controlled Substances Act to make it a prohibited act to remove, alter, or obliterate a required serial number on a tableting machine, encapsulating machine, or critical part. It also prohibits transporting, possessing, or distributing such items knowing the serial number has been tampered with. These provisions aim to prevent evasion of the new tracking requirements.
Section 3(a) & (b)
Extraterritorial Jurisdiction and Enhanced Penalties for Machine Trafficking
This section extends U.S. jurisdiction to cover the manufacture or distribution of tableting/encapsulating machines or critical parts outside the United States, if done with the intent or knowledge that they will be used to illicitly manufacture controlled substances and unlawfully imported into the U.S. It also establishes new, significant penalties (up to 8-15 years imprisonment) for these extraterritorial offenses.
Section 4(a) & (b)
Definition of "Counterfeit Pills Containing an Illicit Synthetic Substance" and Related Prohibited Acts
This section defines "counterfeit pill containing an illicit synthetic substance" to include counterfeit pills containing fentanyl, its analogues, methamphetamine, or other illicit depressants, stimulants, or opioids. It also amends existing law to specifically include fentanyl and its analogues in prohibited acts related to the manufacture or distribution of equipment used to make counterfeit substances.
Section 4(c)
DEA Operation and Response Plan and Annual Reports to Congress
This section mandates the Administrator of the Drug Enforcement Administration (DEA) to establish an operation and response plan within 180 days to address counterfeit pills containing illicit synthetic substances. The plan must include strategies for law enforcement, increased education and prevention efforts (especially for youth), and an audit of current campaigns. Additionally, the Attorney General, in consultation with DEA and ONDCP, must submit annual reports to Congress through fiscal year 2031, detailing data on seizures, markings, substances, geographic origins, and prosecutions related to these counterfeit pills.
This subsection creates an immediate applicability for the serial number record-keeping requirements for existing tableting machines, encapsulating machines, or critical parts manufactured on or before the date of enactment. This requirement begins 180 days after enactment, regardless of when the Attorney General promulgates final regulations for new machines.
Section 2(b)(4)(B)
Why it matters:This is standard legislative practice for phasing in new regulations, ensuring that existing items are brought under the new regime without waiting for the full regulatory process for future items.
Case for: Supporters would argue that regulating existing machines and parts quickly is crucial to prevent a rush to sell or move unregulated equipment before the new rules take full effect, thereby closing a potential loophole for illicit actors.
Case against: Industry groups might argue that imposing record-keeping requirements on existing, potentially untracked, equipment within 180 days could be logistically challenging and costly, especially for businesses with large inventories or older machines lacking serial numbers.
Estimated impact: This provision immediately impacts all current owners and distributors of relevant machinery and parts, requiring them to quickly establish record-keeping for items that may not have previously been tracked with serial numbers.
This provision grants the Attorney General the authority to determine and add "additional parts that the Attorney General has determined to be integral to the operation of a tableting or encapsulating machine" to the definition of "critical part," but only through a formal rulemaking process.
Section 2(a)(5)(D)
Why it matters:This is standard legislative practice to provide administrative agencies with flexibility to adapt regulations to evolving circumstances, while ensuring public input through rulemaking.
Case for: Proponents would argue that this flexibility is necessary to future-proof the bill, allowing the Attorney General to respond to new methods of illicit manufacturing or new machine designs without requiring further legislative action.
Case against: Critics might express concern that this grants broad discretionary power to the Attorney General, potentially leading to future expansions of regulation that could further burden legitimate industry without direct Congressional oversight on each specific addition.
Estimated impact: The immediate impact is the grant of authority; the future impact could be significant if new parts are added, expanding the scope of regulation.